Practice parameter: Risk of driving and Alzheimer’s disease
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with interest the recent practice parameter regarding risk of driving and AD by Dubinsky et al. that was based on a review of epidemiologic studies and driving performance studies assessing crash risk among drivers with AD.1 Two recommendations were made: 1) patients and their families should be told that patients with AD whose Clinical Dementia Rating (CDR) is 1 should not drive because of a substantially increased risk of crashing; and 2) patients and their families should be told that patients with possible AD and a CDR of 0.5 pose a significant traffic problem compared to other elder drivers. In this latter case, clinicians are advised to refer patients for an evaluation of driving performance by a qualified examiner and to assess dementia severity and appropriateness of continued driving every 6 months.
With respect to who is at risk for application of the practice parameter, we studied the prevalence …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
ARTICLES
Cerebral amyloid deposition and diffuse plaques in ``normal'' agingEvidence for presymptomatic and very mild Alzheimer's diseaseJ. C. Morris, M. Storandt, D. W. McKeel, Jr. et al.Neurology, March 01, 1996 -
Articles
Driving and Neurologic DisordersJoseph F. Drazkowski, Joseph I. Sirven et al.Neurology, February 14, 2011 -
Research
Treatment of Dementia With BosutinibAn Open-Label Study of a Tyrosine Kinase InhibitorKennedy D. Mahdavi, Sheldon E. Jordan, Hannah R. Barrows et al.Neurology: Clinical Practice, September 09, 2020 -
Brief Communication
The Clinical Dementia Rating scaleCommunity-based validation of `profound' and `terminal' stagesGeorge Dooneief, Karen Marder, Ming-Xin Tang et al.Neurology, June 01, 1996